Navigation Links
Tianyin Reports Record Fiscal 2010 Financial Results
Date:9/29/2010

10 ended June 30, 2010.

Fiscal year 2010 ending June 30, 2010 financial highlights -- FY2010 revenue exceeds our revenue guidance of $63.0 million for FY2010, up 49.0% year over year (yoy) to $63.9 million from $42.9 million for FY2009 -- Gross profit delivered $33.3 million, up 55.6% yoy from $21.4 million for FY2009 -- Gross margins increased to 52.2% from 49.8% for FY2009 -- Net income rose 51.9% yoy to $12.0 million at 19.0% net margin from $7.9 million at 18.0% net margin for FY2009; the net income also exceeds our net income guidance of $11.0 million for FY2010 -- Earnings per share equals to $0.47 per basic share, or $0.40 per diluted share, up 25.0% year over year from $0.32 per diluted share in FY2009 -- Cash and cash equivalents were $27.0 million on June 30, 2010 as compared to $12.4 million in cash and cash equivalents on June 30, 2009 -- FY2010 operating cash flow rose 85.5% year over year to $15.4 million from $8.3 million in FY2009 FY2010 results FY2010 FY2009 YoY Sales $63.9 million $42.9 million +49.0% Gross Profit $33.3 million $21.4 million +55.6% Operating Income $14.7 million $9.7 million +51.8% Net Income $12.0 million $7.9 million +51.9% EPS (Diluted) $0.40 $0.32 +25.0% Diluted Shares 30.1 million 24.8 million +21.4%

Revenue delivered $63.9 million for the FY2010 up from $42.9 million for FY2009, growing 49.0% yoy, supported by our continuous sales channel expansion and market penetration for our current product portfolio especially the lead products. The results exceeded our targeted $63.0 million FY2010 revenue guidance and validated our growth strategies on sales and marketing, manufacturing capacity expansion along with new pipeline development.

Our lead product revenues are Ginkgo Mihuan Oral Liquid (GMOL): $22.8 million, Apu Shuangxin (Benorylate) Granules (APU) $6.0 million, Xuelian Chongcao Oral Liquid (XLCC): $3.9 million, Azithromycin Dispersible Tablets (AZI): $4.1 million, Qi
'/>"/>

SOURCE Tianyin Pharmaceutical Co., Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Tianyin Corporate Presentation Updated
2. Tianyin Reports Record Third Quarter 2010 Financial Results
3. Tianyin Pharmaceutical Co., Inc. to Present at the 22nd Annual ROTH Capital Partners OC Growth Stock Conference on March 16
4. Tianyin Pharmaceutical Co., Inc. to Present at the 2010 Rodman & Renshaw Annual China Investment Conference in Beijing on March 9
5. Tianyin Pharmaceutical Co., Inc. Expects to Benefit from the Recently Published Guide to Pricing Reform for Medicine and Medical Services
6. Tianyin Pharmaceutical Co., Inc. Announces Record Second Quarter 2010 Financial Results
7. Tianyin Pharmaceutical Co., Inc. Reports Record Fiscal 2009 Financials With $7.9 Million in Net Income
8. Tianyin Pharmaceutical Co., Inc. to Host Fiscal 2009 Earnings Conference Call on Thursday, September 24, 2009 at 10:30 a.m. ET
9. Tianyin Pharmaceutical Co., Inc. Obtains GMP Certification for Its New Production Facility
10. Tianyin Pharmaceutical, Co. to Present at the Rodman & Renshaw Annual Global Investment Conference on September 11 at 10:50 am ET
11. Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA Approval for Sanqi Tablets and Yinqiao Jiedu Tablets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2015)... KS (PRWEB) , ... August 26, 2015 , ... ... Biologic Solutions, announces today that a second US laboratory is to open in ... accordance with the continued partnership and long-term growth of research and development through ...
(Date:8/26/2015)... , Aug. 26, 2015  Platform therapeutic ... it has received a $1.5M Phase II SBIR ... to further develop its therapeutic agent to reduce ... need in end stage renal disease (ESRD) patients ... National Institute of Diabetes and Digestive and Kidney ...
(Date:8/26/2015)... August 26, 2015 Despite ... fueling the optimism in biotech,s forecast is the ... life sciences advancements.  Active biotechnology & healthcare companies ... Inc. (OTCQB: PBIO), Sequenom, Inc. (NASDAQ: SQNM ... Raptor Pharmaceutical Corp. (NASDAQ: RPTP ) and ...
(Date:8/25/2015)... (PRWEB) , ... August 25, 2015 , ... ... at its research facility in Knapp, Wis. The company has added a AS16 ... Fermentor allows detailed data collection during bacterial or fungal fermentation process development. ...
Breaking Biology Technology:MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 2MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 3Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 3New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 2New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 3New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 4New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 5New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 6New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 7New centrifuge and fermentor expand product development capacity at Vets Plus 2
... 13, 2011 Healthpoint Biotherapeutics today announced that Travis ... Bancroft, Executive Vice President, Strategic and Commercial Development, will ... and its R&D pipeline at the upcoming UBS Global ... opening day of the conference, Monday, September 19th, at ...
... CHARLOTTE, N.C., Sept. 13, 2011 Microban recently ... simulate planktonic and biofilm growth on High Consistency ... the manufacture of urinary catheters.  Urinary infections are ... and current technologies have had limited success in ...
... Sept. 13, 2011 Florida-based SkinHealth Technology introduces a ... peptides, polysaccharides and botanical emollients -- with a proven ... skin conditions. ExtremeSkinCare Intense Treatment Balm ... and rosacea and relieve inflamed and irritated skin ...
Cached Biology Technology:Healthpoint Biotherapeutics to Present at UBS Global Life Sciences Conference 2Microban Medical Silver Antimicrobial Technologies for HCR Silicone Achieve 5 Log Reductions in Bacteria Growth and Prevent Biofilm Formation 2New Dermatological Formula Targets Psoriasis, Eczema and Other Extreme Skin Conditions 2
(Date:7/31/2015)... 2015 BGI llevará a cabo la 10ª Conferencia ... 25 de octubre de 2015, en Shenzhen, ... décimo aniversario este año. Desde su inauguración en 2006, ... anuales más influyentes del mundo en los campos de ... más dinámicas, entusiastas y amenas. ICG-10 se ...
(Date:7/31/2015)... La 10 th International Conference on Genomics ... 22 al 25 de octubre de 2015 en ... conferencia celebra su décimo aniversario. Desde su inauguración en el ... reuniones anuales más influyentes del mundo en el campo ,ómico, ... y mejores a nivel científico. ICG-10 se ...
(Date:7/31/2015)... 2015 The 10 th International Conference on ... October 22-25, 2015, in Shenzhen , ... celebrating its 10 th anniversary this year. Since its inauguration ... influential annual meetings in the ,omics, fields, and is one ... ICG-10 focuses on recent breakthroughs and advances in ...
Breaking Biology News(10 mins):La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3The 10th International Conference on Genomics (ICG-10) to Open in October 2
... red seaweed a viable future biofuel? Now that a University ... that can make short work of fermenting galactose, the answer ... crops, they think of corn, miscanthus, and switchgrass. ln small ... marine biomass," said Yong-Su Jin, a U of I assistant ...
... For the first time in history, a change will be ... the Periodic table of the chemical elements posted on walls ... textbooks worldwide. The new table, outlined in a ... elements - hydrogen, lithium, boron, carbon, nitrogen, oxygen, silicon, sulfur, ...
... Ill. Fortified with iron: It,s not just for ... a simpler method of adding iron to tiny carbon ... to remove contaminants from gas or liquid. Civil ... Atkinson and their team described their technique in the ...
Cached Biology News:Seaweed as biofuel? Metabolic engineering makes it a viable option 2Atomic weights of 10 elements on periodic table about to make an historic change 2Atomic weights of 10 elements on periodic table about to make an historic change 3New method for making tiny catalysts holds promise for air quality 2New method for making tiny catalysts holds promise for air quality 3
The Lambda Control Kit contains lambda DNA and two 25mer primers, which can be used to amplify a 500bp fragment. The lambda DNA is purified by CsCl gradient centrifugation and organic extraction foll...
A robust formulation of Taq Polymerase supplied with a 10X colored reaction buffer which allows Direct Gel-Loading...
... derivative of Taq DNA polymerase. It is ... polymerase. Expressed from a gene construct in ... the 5'-3' exonuclease domain of the DNA ... active and even more heat-stable DNA polymerase ...
...
Biology Products: